During an internal meeting, Kennedy voiced concerns over regulatory inefficiencies and the impact of unelected bureaucrats on federal policy, particularly emphasizing the flaws within the FDA.
Kennedy Raises Alarm Over Regulatory Corruption, Aligns with Trump on Deep State Conspiracy
Kennedy Raises Alarm Over Regulatory Corruption, Aligns with Trump on Deep State Conspiracy
Health and Human Services Secretary Robert F. Kennedy Jr. highlights corruption within regulatory agencies, asserting a real influence of the Deep State.
Kennedy's statements come at a critical junction in the political landscape, as he supports President Trump’s earlier claims about embedded corruption in government agencies. In a private meeting with FDA officials and new Commissioner Marty Makary, Kennedy stressed that suspicions long held by the public about a “Deep State” are evident realities influencing policy-making processes.
A specific point of contention for Kennedy is the FDA's “Generally Recognized as Safe” (GRAS) system, which he labeled a serious loophole allowing food companies to bypass extensive safety evaluations for new ingredients. He announced a comprehensive review of the GRAS process to ensure greater public transparency and to combat corporate favoritism that undermines health safety.
Kennedy's critique extends beyond the FDA; he has indicated that “every agency” has become vulnerable to industry influence, showcasing a widespread issue he intends to address. He openly shared his concerns with FDA staff during the campaign, advising them to safeguard their records and prepare for potential personnel changes, portraying an aggressive stance against what he considers a corrupt bureaucratic landscape.
With Kennedy now in a pivotal role within the Biden administration, the duo—a reinvigorated Trump administration alongside Kennedy—appears committed to redefining oversight practices, prioritizing public safety over profit, and striving to restore integrity in the regulatory framework. The actions they vow to take may significantly alter the operational dynamics of U.S. government agencies tasked with protecting citizen welfare.
A specific point of contention for Kennedy is the FDA's “Generally Recognized as Safe” (GRAS) system, which he labeled a serious loophole allowing food companies to bypass extensive safety evaluations for new ingredients. He announced a comprehensive review of the GRAS process to ensure greater public transparency and to combat corporate favoritism that undermines health safety.
Kennedy's critique extends beyond the FDA; he has indicated that “every agency” has become vulnerable to industry influence, showcasing a widespread issue he intends to address. He openly shared his concerns with FDA staff during the campaign, advising them to safeguard their records and prepare for potential personnel changes, portraying an aggressive stance against what he considers a corrupt bureaucratic landscape.
With Kennedy now in a pivotal role within the Biden administration, the duo—a reinvigorated Trump administration alongside Kennedy—appears committed to redefining oversight practices, prioritizing public safety over profit, and striving to restore integrity in the regulatory framework. The actions they vow to take may significantly alter the operational dynamics of U.S. government agencies tasked with protecting citizen welfare.
